CEO of Allarity Therapeutics to Deliver Presentation at Biomarkers & Precision Medicine Conference 2025
AP News: Allarity Therapeutics, Inc., a biopharmaceutical company with exclusive global rights for the development and commercialization of Stenoparib, will present at the Biomarkers & Precision Medicine 2025 conference in London. The presentation titled "A Gene Expression Based Biomarker For Predicting Response To Treatment With Stenoparib" will be delivered by Thomas Jensen, CEO of Allarity Therapeutics, on Wednesday, October 1, 2025, at 4:00 PM. Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. By inhibiting PARP and blocking WNT pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Tankyrases are attracting significant attention as emerging therapeutic targets for cancer, due to their role in regulating the WNT signaling pathway, which has been implicated in the development and progression of numerous cancers. The presentation will focus on the potential utility of Allarity Therapeutics' DRP® companion diagnostic platform to pre-select patients and predict response to stenoparib. The DRP® platform is expected to be discussed in relation to its ability to advance clinical programs. Thomas Jensen will be interviewed by Oxford Global's editorial team, and the interview will be featured on Oxford Global's online content portal. The press release also includes forward-looking statements about the potential utility and benefits of the Company's DRP® companion diagnostic platform. However, it is important to note that the success, timing, and results of clinical trials, the ability to obtain regulatory approval for stenoparib and other product candidates, the company's ability to commercialize its products, secure sufficient capital to fund its operations, protect its intellectual property, and navigate the competitive landscape in the biopharmaceutical industry, all pose risks and uncertainties. Readers are advised to refer to the section entitled "Risk Factors" in the company's Form 10-K annual report for a discussion of other risks and uncertainties. The press release does not provide an update on the information unless required by law. For investor relations queries, please contact [email protected]. The media contact for the press release is Thomas Pedersen from Carrotize PR & Communications. The press release is available at the SEC's website at www.sec.gov.
Read also:
- Trump's SNAP reductions and New York City Council's grocery delivery legislation: Problems for city residents highlighted
- Reducing dental expenses for elderlies in Sweden: Over 50% cut in charges for pensioners by the government
- Forty-year-old diet: A list of meal choices to savor
- Exiled Life's Conundrum: A Blend of Liberation, Disillusionment, and Distress
